Cargando…
It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883560/ https://www.ncbi.nlm.nih.gov/pubmed/34320792 http://dx.doi.org/10.3324/haematol.2021.279457 |
| _version_ | 1784659964923478016 |
|---|---|
| author | Besson, Caroline |
| author_facet | Besson, Caroline |
| author_sort | Besson, Caroline |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8883560 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88835602022-03-18 It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies Besson, Caroline Haematologica Editorials Fondazione Ferrata Storti 2021-07-29 /pmc/articles/PMC8883560/ /pubmed/34320792 http://dx.doi.org/10.3324/haematol.2021.279457 Text en Copyright© 2022 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Editorials Besson, Caroline It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title | It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title_full | It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title_fullStr | It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title_full_unstemmed | It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title_short | It is time to adapt anti-CD20 administration schedules to allow efficient anti-SARS-CoV-2 vaccination in patients with lymphoid malignancies |
| title_sort | it is time to adapt anti-cd20 administration schedules to allow efficient anti-sars-cov-2 vaccination in patients with lymphoid malignancies |
| topic | Editorials |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883560/ https://www.ncbi.nlm.nih.gov/pubmed/34320792 http://dx.doi.org/10.3324/haematol.2021.279457 |
| work_keys_str_mv | AT bessoncaroline itistimetoadaptanticd20administrationschedulestoallowefficientantisarscov2vaccinationinpatientswithlymphoidmalignancies |